Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rajasekhar N. V. S. Suragani"'
Autor:
Ravindra Kumar, Asya V. Grinberg, Huiming Li, Tzu-Hsing Kuo, Dianne Sako, Lavanya Krishnan, Katia Liharska, Jia Li, Rosa Grenha, Michelle C. Maguire, Steven D. Briscoe, R. Scott Pearsall, Brantley R. Herrin, Rajasekhar N. V. S. Suragani, Roselyne Castonguay
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Abstract Ligands of the transforming growth factor-β (TGF-β) superfamily are important targets for therapeutic intervention but present challenges because they signal combinatorially and exhibit overlapping activities in vivo. To obtain agents capa
Externí odkaz:
https://doaj.org/article/3cc08f92090942b6b1e99a5715b4ec9a
Autor:
Jia Li, Maureen Fredericks, Mingxin Tang, Marishka Cannell, Sachindra Joshi, Ravindra Kumar, Patrick Andre, Rajasekhar N. V. S. Suragani
Publikováno v:
FEBS lettersReferences. 596(24)
Cardiomyopathies are ascribed to a variety of etiologies, present with diverse clinical phenotypes, and lack disease-modifying treatments. Mounting evidence implicates dysregulated activin receptor signaling in heart disease and highlights inhibition
Autor:
John D Quisel, Sako Dianne S, Monique V. Davies, Mark J. Alexander, Kathryn W. Underwood, Rajesh Chopra, Ravindra Kumar, Rajasekhar N V S Suragani, Samuel M. Cadena, Jasbir Seehra, R. Scott Pearsall, Kenneth S Loveday, Asya Grinberg, Matthew T. Devine, Robert Li, Dianne C. Mitchell, Sharon M Cawley
Publikováno v:
Nature medicine. 20(4)
Erythropoietin (EPO) stimulates proliferation of early-stage erythrocyte precursors and is widely used for the treatment of chronic anemia. However, several types of EPO-resistant anemia are characterized by defects in late-stage erythropoiesis, whic